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In Brief
 
Membrane Insertion without a Pore
 
The standard pathway of membrane protein insertion in-
volves a recognition and docking step, followed by inser-
tion through a pore. The transfer is terminated by a hydro-
phobic stop-transfer sequence leading to the release of the
partially translocated protein. On page 973, Schleiff et al.
report that a pore is not needed for the correct integration
of the voltage-dependent anion-selective channel, VDAC,
into the mitochondrial outer membrane.
The recognition and pore complexes in the mitochon-
drial outer membrane are based around the proteins
 
Tom20 and Tom40, respectively. Blockade of Tom40
function with unfoldable proteins or a temperature-sensi-
tive Tom40 mutant does not prevent VDAC import, and
Tom40 is not necessary for integration of functional
VDAC into synthetic vesicles. Tom20 is necessary for
VDAC integration into vesicles, however. Tom20 may
function simply by increasing the local concentration of
VDAC at the membrane, or it may have a more active role
in releasing bound chaperones or inducing a conforma-
tional change that aids insertion.
A similar discovery in the 1970s, that an M13 coat pro-
tein could insert into membranes without the need for a
channel, temporarily threatened the introduction of the
signal hypothesis, but this case was subsequently recog-
nized to be an exception. VDAC, however, is a cellular
protein, and a member of a widespread group of proteins
 
with a 
 
b
 
-barrel conformation. Tom40 has some of the
characteristics of a 
 
b
 
-barrel protein. Perhaps the VDAC
insertion mechanism is the answer to the chicken-and-egg
evolutionary problem of how the first integral proteins,
and the transport pores themselves, were inserted into
membranes.
 
Motility Driven by Branched Nucleation
 
At the light-microscope level, membrane protrusion dur-
ing cell movement is driven by actin polymerization at the
leading edge. The actin is then turned over by depolymer-
ization at variable distances away from the leading edge.
The simplest interpretation of these observations is that
motility is driven by the treadmilling growth of long actin
filaments. Svitkina and Borisy (page 1009) take a closer
look at actin filaments by electron microscopy and find
support for another theory in which there is limited fila-
ment growth, but frequent nucleation, of a branched net-
work that can adapt to rapid changes. In this theory, it is
the network, rather than the individual filament, that
treadmills.
The Borisy group has observed the branched network in
fish keratinocytes, but needed to switch to frog cells so
that they could use antibodies. Use of these antibodies
now confirms that the Arp2/3 complex (composed of ac-
tin-related proteins 2 and 3 and five other proteins) is at
the Y-junctions. Arp2/3 can nucleate actin polymerization,
cap pointed ends, and bind those pointed ends to the side
of existing filaments. Branching is frequent, so most of the
distal (barbed) ends must be capped to prevent an expo-
nential increase in the amount of actin. The emphasis on
multiple nucleation events in this model provides plenty of
scope for explosive actin growth when the cell needs to ac-
celerate or change direction.
The dense branched network, or brush, extends back for
 
only 
 
z
 
1 
 
m
 
m, at which point it reverts to a looser, more
readily depolymerized actin network. Cofilin could effect
this transition through its severing or pointed-end depoly-
merization activities, but other factors must be limiting its
action, as cofilin is present at the rear of the keratinocyte
brush and throughout the fibroblast brush. The factor that
spatially controls depolymerization may be displacing the
Arp2/3 complex, thus exposing pointed ends.
 
Mitotic Checkpoints
 
Bub2 Branches Off
 
Six budding yeast mutants, 
 
mad1
 
, 
 
mad2
 
, 
 
mad3
 
, 
 
bub1
 
,
 
bub2
 
, and 
 
bub3
 
, fail to arrest in mitosis when their spindles
are disrupted with drugs such as nocodazole. Four re-
search groups, including Fraschini et al. in this issue (page
979), now show that these checkpoint proteins fall into two
pathways. Five of the proteins appear to prevent anaphase
onset until chromosomes are attached to the spindle, but
Bub2p defines a separate pathway that may prevent cyto-
kinesis onset until anaphase is either completed or well
underway.
Bub2p has looked different in the past: it does not local-
ize to the kinetochore (as do several mitotic checkpoint
proteins), and the 
 
bub2
 
 mutant cells still delay when con-
fronted with chromosomes with defective kinetochores.
Therefore, Fraschini et al. looked at 
 
mad2 bub2
 
 double
mutants, and found that they were more sensitive to mi-
crotubule-depolymerizing drugs than either single mutant.
The double mutants rereplicated faster and more effi-
ciently in nocodazole than the single mutants, acting as
though no drug were present.
Fraschini et al. and Alexandru et al. (Alexandru, G., W.
Zachariae, A. Schleiffer, and K. Nasmyth. 1999. 
 
EMBO
(Eur. Mol. Biol. Organ.) J. 
 
18:2707Ð2721) find that the
Mad2p pathway is preventing the destruction of the ana-
phase inhibitor Pds1p and therefore chromosome disjunc-
tion. In contrast, the Bub2p pathway is preventing the de-
struction of mitotic kinase activity, and thus the final exit
from mitosis, by controlling Clb2p cyclin levels and per-
haps other regulators. Although a full mitosis checkpoint
defect seems to require the removal of two systems, the
isolation of the original single mutants was possible be-
cause the systems cover slightly different events, and be-
cause of leakiness between the two checkpoints.
Li (Li, R. 1999. 
 
Proc
 
.
 
 Natl
 
.
 
 Acad
 
.
 
 Sci
 
.
 
 USA.
 
 96:4989Ð
4994) and Fesquet et al. (Fesquet, D., P.J. Fitzpatrick, A.L.
Johnson, K.M. Kramer, J.H. Toyn, and L.H. Johnston. 
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1999. 
 
EMBO (Eur. Mol. Biol. Organ.) J.
 
 18:2424Ð2434)
use different proteins as starting points, but come to simi-
lar conclusions. Fesquet et al. find that Bub2p, but not the
other checkpoint proteins, turns off Dbf2p protein kinase
activity in the presence of nocodazole. Dbf2p is one of a
group of proteins needed for mitotic exit. Alexandru et
al. and Li both use sequence similarity to identify the bud-
ding yeast version of Byr4p (Li names this protein Bfa1p
for Byr-four-alike). In fission yeast, Byr4p acts with the
Bub2p homologue, Cdc16p, as a two-component GTPase
activating protein and negative regulator of cytokinesis.
Mutants in budding yeast 
 
byr4
 
 act like 
 
bub2
 
: they are sen-
sitive to nocodazole, and show increased sensitivity when
combined with 
 
mad2
 
.
Both Bub2p (Li, 1999; Fraschini et al.) and Bfa1p/Byr4p
(Li, 1999) localize to spindle poles. These proteins may
sense the arrival of chromosomes at the poles at the end of
anaphase and only then allow the initiation of cytokinesis.
Controlling cytokinesis onset is very important in budding
yeast, where the site of cell division (the bud neck) is
formed very early in the cell cycle.
 
Checkpoints and Microtubule Dynamics
 
On page 993, Tirnauer et al. report that Bim1p is the first
nonmotor budding yeast protein known to promote dy-
namic instability of microtubules. Bim1p promotes dy-
namics during G1, when dynamic microtubules are needed
to position the newly formed spindle.
Yeast cells that lack Bim1p have shorter microtubules in
G1 relative to wild-type cells. The microtubules have fewer
catastrophe and rescue events, shrink more slowly, and
spend far more time pausing. The sum of these effects is to
reduce microtubule dynamics to below the level normally
seen in mitosis.
The mammalian version of Bim1p is EB1. Taxol dis-
places EB1 from microtubules, which may in part explain
why taxol suppresses microtubule dynamics.
EB1 binds the domain of the adenomatous polyposis
coli (APC) tumor suppressor protein that is deleted in co-
lon carcinoma. The cancer connection for EB1 may be
checkpoints. Bim1p functions in a recently identified nu-
clear positioning checkpoint (which is not identical to, but
may be connected to, the Bub2p checkpoint mentioned
 
above). This checkpoint is important for yeast growing
outside the laboratory, where frequent low temperatures
cause depolymerization of astral microtubules and a fail-
ure of the nucleus to line up in the bud neck. Both EB1
and Bim1p bind the plus end of microtubules, so perhaps
the yeast cell uses Bim1pÕs arrival at the cortex of the cell
as the signal that astral microtubules have successfully
found their way into both mother and daughter cells.
 
Why a Synapsin Mutant Mouse Has Epilepsy
 
The splice products of three synapsin genes anchor synap-
tic vesicles to each other and to the cytoskeleton. Mice
that lack synapsin I survive with few gross consequences,
but are prone to epilepsy. On page 1039, Terada et al. pro-
vide an explanation for the epilepsy.
When mutant inhibitory neurons in culture are first
stimulated, they release a normal burst of neurotransmit-
ter. Subsequent intense stimulation, however, elicits less
than half the normal number of neurotransmitter quanta.
After stimulation of mutant inhibitory neurons, there are
fewer vesicles in regions away from the synaptic cleft.
Based on these data and other measurements of neu-
rotransmitter release, Terada et al. suggest that the mutant
neurons fail to withhold a majority of vesicles in a reser-
voir pool, instead releasing most vesicles upon strong stim-
ulation. The neurons are then temporarily unable to re-
spond to further stimulation.
Repeated neurotransmitter release is normal in excita-
tory neurons, possibly because synapsin II can substitute
for synapsin I in these cells. The imbalance between nor-
mal excitatory signals and insufficient inhibitory signals af-
ter strong stimulation, provides a plausible explanation for
the epilepsy in the mutant mice.
Whereas most mice with epilepsy have learning prob-
lems, both the synapsin I mutant mice and most humans
with epilepsy have no learning deficit. These mice may
therefore provide a better model for human epilepsy.
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